Evotec SE

EVTGermany

22 filed reports · 245 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

—

Net income

-€196M

FY2024 · to Dec 31, 2024

a year earlier: -€83.9M

Annual report

Operating income

—

Latest half year

Revenue

€300M

H1 FY2026 · to Jun 30, 2026

down −19.2% vs €371M

Half-year report

Net income

-€169M

H1 FY2026 · to Jun 30, 2026

Half-year report

Operating income

-€235M

H1 FY2026 · to Jun 30, 2026

a year earlier: -€47.8M

Half-year report

Filed reports

22 reports · Sep 2018 to Jun 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Half YearBundesanzeiger6625Jun 2021 to Jun 2026
Q3Bundesanzeiger6565Sep 2018 to Sep 2025
AnnualBundesanzeiger5375Dec 2021 to Dec 2025
Q1Bundesanzeiger5296Mar 2021 to Mar 2026

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q2half year2026-06-302026-06-30100Open
FY2026 Q1q12026-03-312026-03-3179Open
FY2025annual2025-12-312026-04-0873Open
FY2025 Q3q32025-09-302025-09-3097Open
FY2025 Q2half year2025-06-302025-06-30108Open
FY2025 Q1q12025-03-312025-03-3165Open
FY2024annual2024-12-312025-04-1795Open
FY2024 Q3q32024-09-302024-09-30109Open
FY2024 Q2half year2024-06-302024-06-30110Open
FY2024 Q1q12024-03-312024-03-3175Open
FY2023annual2023-12-312023-12-3196Open
FY2023 Q3q32023-09-302023-09-3094Open

Financial data

245 concepts · 1,861 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

IFRS226 concepts · 1,730 facts · Sep 2018 to Jun 2026

  • Income Tax Expense (Benefit)31 · Mar 2021 to Dec 2025
  • R&D Expense31 · Sep 2018 to Jun 2026
  • Contract liabilities29 · Sep 2018 to Jun 2026
  • Provisions29 · Sep 2018 to Jun 2026
  • Cost of Revenue28 · Sep 2018 to Jun 2026
  • Gross Profit28 · Sep 2018 to Jun 2026
  • Revenue28 · Sep 2018 to Jun 2026
  • SG&A Expense28 · Sep 2018 to Jun 2026
  • Weighted average shares outstanding28 · Sep 2018 to Jun 2026
  • Income before taxes26 · Mar 2021 to Sep 2025
  • Operating Income26 · Sep 2018 to Jun 2026
  • — Other operating income26 · Sep 2018 to Jun 2026
  • Total non-operating income (expense)24 · Sep 2018 to Sep 2025
  • — Share of the result of associates accounted for using the equity method23 · Jun 2021 to Sep 2025
  • — Other operating expense22 · Mar 2021 to Sep 2025
  • Total operating income (expense)22 · Mar 2021 to Sep 2025
  • Net Income21 · Sep 2018 to Jun 2026
  • Interest20 · Dec 2022 to Dec 2025
  • — Measurement result from investments18 · Mar 2022 to Sep 2025
  • Net cash provided by (used in) financing activities18 · Mar 2021 to Jun 2026
  • Net income per share (basic)18 · Mar 2021 to Sep 2025
  • Net income per share (diluted)18 · Mar 2021 to Sep 2025
  • — Other non-operating income (expense), net18 · Jun 2021 to Sep 2025
  • Inventory17 · Sep 2018 to Jun 2026

Segment18 concepts · 130 facts · Sep 2018 to Jun 2026

  • Gross Profit20 · Sep 2018 to Jun 2026
  • Revenue18 · Jun 2021 to Jun 2026
  • SG&A Expense14 · Sep 2018 to Mar 2025
  • R&D Expense12 · Jun 2021 to Jun 2026
  • Net Income10 · Dec 2023 to Dec 2024
  • Operating Income9 · Jun 2021 to Jun 2026
  • Cost of Revenue8 · Jun 2021 to Jun 2026
  • — Other operating income7 · Sep 2018 to Jun 2026
  • Other operating income (expenses), net6 · Sep 2021 to Sep 2023
  • Reorganization costs5 · Sep 2024 to Jun 2026
  • Adjusted EBITDA4 · Sep 2018 to Jun 2026
  • Other operating income4 · Mar 2026 to Jun 2026
  • Other operating expense 4)3 · Sep 2024 to Mar 2025
  • External revenues2 · Sep 2018
  • Impairments of intangible assets2 · Sep 2018 to Sep 2023
  • Net operating income (loss)2 · Sep 2023
  • Other operating expenses2 · Sep 2018
  • plus change in contingent consideration (earn-out)2 · Jun 2021

KPI1 concept · 1 fact · Mar 2025

  • Gross Profit1 · Mar 2025

Segments

130 facts

Figures broken down by business line, region, product or another axis the company reports on.

Operating segment6 members · 116 facts

  • EVT Execute35 · Sep 2018 to Sep 2023
  • EVT Innovate35 · Sep 2018 to Sep 2023
  • Shared R&D14 · Jun 2024 to Mar 2025
  • D&PD13 · Mar 2026 to Jun 2026
  • Just - Evotec Biologics10 · Sep 2024 to Mar 2025
  • JEB9 · Mar 2026 to Jun 2026

Associate company8 members · 14 facts

  • Quantro Therapeutics GmbH4 · Dec 2023 to Dec 2024
  • Centauri Therapeutics GmbH2 · Dec 2023
  • Centauri Therapeutics Ltd2 · Dec 2024
  • Dark Blue Therapeutics Ltd2 · Dec 2023 to Dec 2024
  • Autobahn Labs LLC1 · Dec 2023
  • Curexsys GmbH1 · Dec 2023
  • EIR Biotherapies1 · Dec 2024
  • Topas Therapeutics GmbH1 · Dec 2024

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of Evotec SE (EVT) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.

Evotec SE (EVT): FY2024 net income -€196M · FactIQ